Glucarpidase
- Generic Name
- Glucarpidase
- Brand Names
- Voraxaze
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9074-87-7
- Unique Ingredient Identifier
- 2GFP9BJD79
- Background
Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified Escherichia coli bacteria. It is a 390-amino acid homodimer protein. High-dose methotrexate, an antifolate agent, has been widely and safely used for many decades in treating various cancers; however, even with aggressive hydration, urine alkalinization, and leucovorin rescue,...
- Indication
Glucarpidase is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per litre) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired...
- Associated Conditions
- Methotrexate toxicity
- Associated Therapies
- -
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Protherics Medicines Development Limited
- Target Recruit Count
- 1000
- Registration Number
- NCT05899751
- Locations
- 🇪🇸
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Barcelona, Spain
🇫🇷Assistance Publique Hôpitaux de Marseille (APHM), La Timone Hospital, Marseille, France
🇪🇸Fundación Privada Instituto de Investigación Oncológica de Vall d'Hebron (VHIO), Barcelona, Spain
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 18
- Registration Number
- NCT05135858
- Locations
- 🇫🇷
Hôpital Pitié-Salpêtrière, Paris, France
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04668768
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03960177
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT03684980
- Locations
- 🇺🇸
Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 34
- Registration Number
- NCT02022358
- Locations
- 🇬🇧
University College Hospital, London, United Kingdom
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2018-09-28
- Target Recruit Count
- 47
- Registration Number
- NCT01305655
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇩🇰Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark
🇳🇴University Hospital of Trondheim, Trondheim, Norway
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Conditions
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- University College, London
- Target Recruit Count
- 4
- Registration Number
- NCT00727831
- Locations
- 🇬🇧
Leeds General Infirmary, Leeds, England, United Kingdom
🇬🇧Torbay Hospital, Torquay, England, United Kingdom
High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- BTG International Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00634322
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00018967
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.